Ipsogen SA (Alternext: ALIPS) today announced that a new study confirming the pivotal role of tumor grade in chemotherapy prescription has been presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), December 9-13, 2009.
The study was conducted at Institut Paoli Calmettes (IPC) Cancer Centre, Marseille, France. Using the centre database and a classification tree method, it retrospectively examined the tumor and patient characteristics driving prescription of adjuvant chemotherapy for 5854 early stage node negative (M-/N-), invasive breast cancer (IBC) patients treated between 1999 and 2005.
The study results indicate that tumor grade is the most contributive factor for adjuvant chemotherapy in N-/M- IBC, together with tumor size. Hierarchy of factors driving chemotherapy decision is remarkably stable over time, despite the progressive availability of new pathologic indicators over time.
"These new findings further support the value of Genomic Grade -a tool to refine tumor grading by resolving intermediate histologic grade 2 tumors in which indication of chemotherapy is a clinical challenge - for treatment decision making. Integrated in currently validated treatment algorithms using tumor grade, the Genomic Grade could contribute to a more individualized chemotherapy strategy in Invasive Breast Cancer" comments H?Šl??ne Peyro-Saint-Paul, Ipsogen Chief Medical Officer.
The study was presented at Poster Session 2, Friday, Dec 11, 2009, abstract # 2089:
Title: Real-life implementation of treatment guidelines for adjuvant chemotherapy in invasive breast cancer: retrospective analysis of a large single centre 10-year database.
Jean-Marie Boher, Jean-Marc Extra, Jacques Camerlo, Carole Tarpin, Emmanuelle Charaffe-Jauffret, Eric Lambaudie, Agnes Tallet, H?Šl??ne Peyro-Saint-Paul, Patrice Viens
Source
Ipsogen